DOCSLIB.ORG

Nsaids Separation on HALO 2 ES-CN with MS Compatible Mobile Phase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nsaids Separation on HALO 2 ES-CN with MS Compatible Mobile Phase Application Note: 128-NS NSAIDs Separation on HALO 2 ES-CN with MS Compatible Mobile Phase 3 G0112 1 PEAK IDENTITIES: 5 1. Aspirin 2. Tolmetin 3. Naproxen 4. Fenoprofen 2 5. Ibuprofen 6. Diclofenac 4 6 Absorbance @ 230 nm @ 230 Absorbance 0.0 0.2 0.4 0.6 0.8 1.0 Minutes TEST CONDITIONS: STRUCTURES: Column: 3.0 x 50 mm, HALO 2 ES-CN Part Number: 91813-404 Mobile Phase: 60/40-A/B A= Water with 0.1% formic acid/ 10 mM ammonium formate, pH 3.3 B= 80/20 Acetonitrile/Water with 0.1% formic acid/10 mM ammonium formate Flow Rate: 2.0 mL/min. Pressure: 440 bar Aspirin Naproxen Ibuprofen Temperature: 45 °C Detection: UV 230 nm, PDA Injection Volume: 1 μL Sample Solvent: Water/methanol Data Rate: 80 Hz Response Time: 0.02 sec. Flow Cell: 2 μL micro cell LC System: Agilent 1200 SL Tolmetin Fenoprofen Diclofenac Six NSAIDS are separated on a HALO 2 ES -CN column using a MS compatible mobile phase in less than 1 minute with symmetrical peak shape s. FOR MORE INFORMATION OR TO PLACE AN ORDER, CONTACT: www.advanced-materials-tech.com ® HALO and Fused-Core are registered trademarks of Advanced Materials Technology, Inc. Application Note: 074-NS Separation of NSAIDs on HALO-5 and Totally Porous 5 µm 3 G0057 1 HALO-5 C18 4 5 PEAK IDENTITIES: 2 1. Acetaminophen 6 8 9 7 2. Aspirin 3. Salicylic acid 4. Tolmetin 3 1 STRUCTUR 5. Ketoprofen Totally Porous 5 µm C18 6. Naproxen 2 4 5 Absorbance @ 254 nm 6 7 8 9 7. Fenoprofen 8. Diclofenac 9. Ibuprofen 0 2 4 6 8 10 12 14 16 18 Time, min. TEST CONDITIONS: STRUCTURES: Columns: 4.6 x 150 mm, HALO-5 C18 (Part number: 95814 - 702) and a 4.6 x 150 mm, 5 µm totally porous C18 column A = 20 mM Potassium phosphate, pH 2.5 B = 50/50 (v/v) Acetonitrile/methanol Composition: 48/52: A/B Flow Rate: 2.0 mL/min. Pressure: 240 bar on HALO-5 C18 Acetaminophen Tolmetin Fenoprofen 215 bar on totally porous 5 µm Temperature: 30 °C Detection: UV 254 nm, VWD Injection Volume: 2 µL Sample Solvent: 50:50 Methanol/water Response Time: 0.02 sec. Flow Cell: 2.5 µL, semi-micro LC System: Shimadzu Prominence UFLC XR Aspirin Ketoprofen Diclofenac Extracolumn volume: ~14 µL The HALO-5 column separates this mixture of NSAIDs (non-steroidal anti- inflammatory drugs) in less than 60% of the time and with better resolution than a Salicylic acid Ibuprofen Naproxen typical HPLC column packed with totally porous, 5 - micron particles. FOR MORE INFORMATION OR TO PLACE AN ORDER, CONTACT: www.advanced -materials-tech.com ® HALO and Fused-Core are registered trademarks of Advanced Materials Technology, Inc. Application Note: 56-NS Isocratic Separation of NSAIDs on HALO ES-CN Phase G0038 5 6 PEAK IDENTITIES: 1. Acetaminophen 8 2. Aspirin 3. Salicylic acid 4 2 4. Tolmetin 5. Naproxen 6. Fenoprofen 1 9 7. Ibuprofen 7 8. Diclofenac Absorbance 3 9. Mefenamic acid 0.0 0.2 0.4 0.6 0.8 1.0 Minutes TEST CONDITIONS: STRUCTURES: Column: 4.6 x 50 mm, HALO ES-CN Part Number: 92814-404 Mobile Phase: 50/50-A/B A= 0.02 M potassium phosphate buffer, pH=2.5 B=Acetonitrile Flow Rate: 2.0 mL/min. Pressure: 165 Bar Acetaminophen Tolmetin Ibuprofen Temperature: 35 °C Detection: UV 230 nm, VWD Injection Volume: 0.5 μL Sample Solvent: Water/methanol Response Time: 0.02 sec. Flow Cell: 2.5 μL semi-micro LC System: Shimadzu Prominence UFLC XR Extra column volume: ~14 μL Aspirin Naproxen Diclofenac This separation illustrates the separating power of HALO Fused-Core stationary phases. Nine NSAID drugs are separated in under one minute on a 50 mm HALO ES-CN column. Salicylic acid Fenoprofen Mefenamic acid FOR MORE INFORMATION OR TO PLACE AN ORDER, CONTACT: www.advanced-materials-tech.com ® HALO and Fused-Core are registered trademarks of Advanced Materials Technology, Inc. Application Note: 016-NS Gradient Separation of NSAIDS on HALO RP-Amide 9 10 PEAK IDENTITIES: 1. Acetaminophen 2. Aspirin 3. Salicylic acid 4. Tolmetin 5. Ketoprofen 4 5 1 6 7 6. Naproxen 8 7. Fenoprofen 8. Ibuprofen 2 9. Diclofenac Absorbance 10. Mefenamic acid i=impurity 3 i i 0 0.5 1 1.5 2 2.5 3 3.5 Minutes TEST CONDITIONS: STRUCTURES: Column: 4.6 x 50 mm, HALO RP-Amide, 2.7 µm Part Number: 92814-407 Mobile Phase: 50/50-- A/B (start) A= 0.02 M sodium phosphate buffer, pH=2.5 B= methanol Acetaminophen Naproxen Gradient: 0.0 min 50%B 0.1 min 50%B 0.5 min 55%B 3.5 min 80%B 4.0 min 80%B Fenoprofen Flow Rate: 2.0 mL/min. Aspirin Pressure: 289 Bar Temperature: 35°C Detection: UV 254 nm, VWD Injection Volume: 1.0 μL Sample Solvent: mobile phase Salicylic acid Diclofenac Response Time: 0.02 sec. Flow Cell: 2.5 μL semi-micro LC System: Shimadzu Prominence UFLC XR Extra column volume: ~14 μL Tolmetin Ibuprofen Ten non-steroidal anti-inflammatory drugs (NSAIDS) can be separated in under 3.5 minutes using a short HALO RP-Amide 2.7 µm packed column. Ketoprofen Mefenamic acid FOR MORE INFORMATION OR TO PLACE AN ORDER, CONTACT: www.advanced-materials-tech.com ® HALO and Fused-Core are registered trademarks of Advanced Materials Technology, Inc. Application Note: 015-NS Separation of NSAIDS on HALO C8 8 5 6 PEAK IDENTITIES: 1. Acetaminophen 7 2. Aspirin 10 3. Salicylic acid 4. Tolmetin 5. Ketoprofen 9 6. Naproxen Absorbance 7. Fenoprofen 8. Diclofenac 9. Ibuprofen 3 i 10. Mefenamic acid i=impurity 0 0.5 1 1.5 2 2.5 3 3.5 Minutes TEST CONDITIONS: STRUCTURES: Column: 4.6 x 50 mm, HALO C8, 2.7µm Part Number: 92814-408 Mobile Phase: 35/65-- A/B A= 0.02 M sodium phosphate buffer, pH=2.5 B= methanol Acetaminophen Naproxen Flow Rate: 2.0 mL/min. Pressure: 277 Bar Temperature: 35°C Detection: UV 254 nm, VWD Injection Volume: 1.0 μL Sample Solvent: mobile phase Fenoprofen Aspirin Response Time: 0.02 sec. Flow Cell: 2.5 μL semi-micro LC System: Shimadzu Prominence UFLC XR Extra column volume ~14 μL Salicylic acid Diclofenac Tolmetin Ibuprofen Ketoprofen Mefenamic acid FOR MORE INFORMATION OR TO PLACE AN ORDER, CONTACT: www.advanced-materials-tech.com ® HALO and Fused-Core are registered trademarks of Advanced Materials Technology, Inc. Application Note: 14-NS Gradient Separation of NSAIDS on HALO C8 PEAK IDENTITIES: 1. Acetaminophen 2. Aspirin 3. Salicylic acid 4. Tolmetin 5. Ketoprofen 6. Naproxen 7. Fenoprofen 8. Diclofenac 9. Ibuprofen 10. Mefenamic acid TEST CONDITIONS: STRUCTURES: Column: 4.6 x 50 mm, HALO C8 Part Number: 92814-408 Mobile Phase: 38/62-- A/B (start) A= 0.02 M sodium phosphate buffer, pH=2.5 B= methanol Acetaminophen Naproxen Gradient: 0.0 min 62%B 0.1 min 62%B 2.0 min 85%B Flow Rate: 2.0 mL/min. Pressure: 286 Bar Fenoprofen Aspirin Temperature: 35°C Detection: UV 254 nm, VWD Injection Volume: 1.0 μL Sample Solvent: mobile phase Response Time: 0.02 sec. Flow Cell: 2.5 μL semi-micro Salicylic acid Diclofenac LC System: Shimadzu Prominence UFLC XR ECV: ~14 μL Tolmetin Ibuprofen Ketoprofen Mefenamic acid FOR MORE INFORMATION OR TO PLACE AN ORDER, CONTACT: www.advanced-materials-tech.com ® HALO and Fused-Core are registered trademarks of Advanced Materials Technology, Inc. Application Note: 013-NS Isocratic Separation of NSAIDS on HALO C18 1 4 5 2 PEAK IDENTITIES: 3 1. Acetaminophen 6 2. Aspirin 3. Salicylic acid 4. Tolmetin 5. Ketoprofen 6. Naproxen 7 7. Fenoprofen Absorbance 8 8. Diclofenac 9 9. Ibuprofen 0.0 0.5 1.0 1.5 2.0 Minutes TEST CONDITIONS: STRUCTURES: Column: 4.6 x 50 mm, HALO C18 Part Number: 92814-402 Mobile Phase: 43/57 A/B A= 0.02 M sodium phosphate buffer, pH=2.5 B=(methanol/ACN)-50/50 Acetaminophen Naproxen Flow Rate: 3.0 mL/min. Pressure: 338 Bar Temperature: 35°C Detection: UV 254 nm, VWD Injection Volume: 1.0 μL Sample Solvent: methanol/ water-50/50 Aspirin Fenoprofen Response Time: 0.02 sec. Flow Cell: 2.5 μL semi-micro LC System: Shimadzu Prominence UFLC XR Extra column volume: ~14 μL Salicylic acid Diclofenac Tolmetin Ibuprofen Ketoprofen FOR MORE INFORMATION OR TO PLACE AN ORDER, CONTACT: www.advanced-materials-tech.com ® HALO and Fused-Core are registered trademarks of Advanced Materials Technology, Inc. .
Load more

Recommended publications
  • Synthesis of Aspirin
    SYNTHESIS OF ASPIRIN I. OBJECTIVES AND BACKGROUND You will: synthesize acetylsalicylic acid (aspirin) by carrying out a simple organic reaction, separate your product from the reaction mixture by vacuum filtration, purify your product by recrystallization, perform a chemical test to identify the change in functional group from reactant to product, and determine the success of your synthesis by calculating the percentage yield of your product. INTRODUCTION Aspirin is one of the most widely used medications in the world. It is employed as an analgesic (pain relief), an anti-pyretic (fever control) and an anti-inflammatory. More recently, studies have indicated that daily intake of small doses of aspirin can lower the risk of heart attack and stroke in high-risk patients. The history of aspirin and its precursor dates back to ancient times. Documents attributed to Hippocrates, the father of modern medicine, from the 4th century B.C. refer to the alleviation of pain by chewing on the bark of a willow tree or ingesting a powder made from the bark and leaves of the willow. This remedy was passed on from generation to generation. Fast forward now to the 19th century, where the field of organic chemistry began to experience tremendous growth. By 1838, chemists had managed to isolate, purify and identify the component of willow bark that provided the analgesic benefit. The compound was named salicylic acid, which was based on the genus name of the willow. Efforts to market salicylic acid met with failure, due to an unfortunate side effect-- prolonged ingestion of salicylic acid led to stomach pain, and in some cases, ulcers.
    [Show full text]
  • Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep
    animals Article Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep Shashwati Mathurkar 1,*, Preet Singh 2 ID , Kavitha Kongara 2 and Paul Chambers 2 1 1B, He Awa Crescent, Waikanae 5036, New Zealand 2 School of Veterinary Sciences, College of Sciences, Massey University, Palmerston North 4474, New Zealand; [email protected] (P.S.); [email protected] (K.K.); [email protected] (P.C.) * Correspondence: [email protected]; Tel.: +64-221-678-035 Received: 13 June 2018; Accepted: 16 July 2018; Published: 18 July 2018 Simple Summary: Scarcity of non-steroidal anti-inflammatory drugs (NSAID) to minimise the pain in sheep instigated the current study. The aim of this study was to know the pharmacokinetic parameters of salicylic acid in New Zealand sheep after administration of multiple intravenous and oral doses of sodium salicylate (sodium salt of salicylic acid). Results of the study suggest that the half-life of the drug was shorter and clearance was faster after intravenous administration as compared to that of the oral administration. The minimum effective concentration required to produce analgesia in humans (16.8 µL) was achieved in sheep for about 0.17 h in the current study after intravenous administration of 100 and 200 mg/kg body weight of sodium salicylate. However, oral administration of these doses failed to achieve the minimum effective concentration as mentioned above. This study is of significance as it adds valuable information on pharmacokinetics and its variation due to breed, species, age, gender and environmental conditions.
    [Show full text]
  • KETOFEN ® (Ketoprofen)
    See other side for instructions for use in cattle. KETOFEN® (ketoprofen) Injectable Solution, 100 mg/mL For intravenous use in horses. PHARMACOLOGY KETOFEN is a non-narcotic, non-steroidal anti-inflammatory agent CAUTION with analgesic and antipyretic properties. Federal law restricts this drug to use by or on the order of a In horses, intravenous dosages of ketoprofen ranging from licensed veterinarian. 0.5 to 1.5 mg/lb resulted in dosage dependent anti-inflammatory effects in the chronic adjuvant carpitis model as depicted in the DESCRIPTION following graph. Ketoprofen is a non-steroidal anti-inflammatory agent of the propionic acid class that includes ibuprofen, naproxen and fenoprofen. Active Ingredient: Each mL contains 100 mg ketoprofen/mL of aqueous solution. Inactive Ingredients: 70 mg L-Arginine/mL; citric acid (to adjust pH); benzyl alcohol, 0.025 g (as preservative). It is packaged in a multiple dose bottle. INDICATION KETOFEN® (ketoprofen) is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. DOSAGE AND ADMINISTRATION The recommended dosage is 1 mg/lb (1 mL/100 lbs) of body weight administered intravenously once daily. Treatment may be repeated for up to five days. Onset of activity is within two hours with peak response by 12 hours. Use contents within 4 months of first vial puncture. CONTRAINDICATIONS Additional studies using the same model in horses have There are no known contraindications to this drug when used as shown that the effects of ketoprofen are maximal by 12 hours directed. and still measurable at 24 hours after each dosage as depicted in Intra-arterial injection should be avoided.
    [Show full text]
  • Salsalate Tablets, USP 500 Mg and 750 Mg Rx Only
    SALSALATE RX- salsalate tablet, film coated ANDAPharm LLC Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- Salsalate Tablets, USP 500 mg and 750 mg Rx Only Cardiovascular Risk NSAIDs may cause an increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS and CLINICAL TRIALS). Salsalate tablets, USP is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (See WARNINGS). Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS). DESCRIPTION Salsalate, is a nonsteroidal anti-inflammatory agent for oral administration. Chemically, salsalate (salicylsalicylic acid or 2-hydroxybenzoic acid, 2-carboxyphenyl ester) is a dimer of salicylic acid; its structural formula is shown below. Chemical Structure: Inactive Ingredients: Colloidal Silicon Dioxide, D&C Yellow #10 Aluminum Lake, Hypromellose, Microcrystalline Cellulose, Sodium Starch Glycolate, Stearic Acid, Talc, Titanium Dioxide, Triacetin. CLINICAL PHARMACOLOGY Salsalate is insoluble in acid gastric fluids (<0.1 mg/mL at pH 1.0), but readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid.
    [Show full text]
  • Nsaids: Dare to Compare 1997
    NSAIDs TheRxFiles DARE TO COMPARE Produced by the Community Drug Utilization Program, a Saskatoon District Health/St. Paul's Hospital program July 1997 funded by Saskatchewan Health. For more information check v our website www.sdh.sk.ca/RxFiles or, contact Loren Regier C/O Pharmacy Department, Saskatoon City Hospital, 701 Queen St. Saskatoon, SK S7K 0M7, Ph (306)655-8506, Fax (306)655-8804; Email [email protected] We have come a long way from the days of willow Highlights bark. Today salicylates and non-steroidal anti- • All NSAIDs have similar efficacy and side inflammatory drugs (NSAIDs) comprise one of the effect profiles largest and most commonly prescribed groups of • In low risk patients, Ibuprofen and naproxen drugs worldwide.1 In Saskatchewan, over 20 may be first choice agents because they are different agents are available, accounting for more effective, well tolerated and inexpensive than 300,000 prescriptions and over $7 million in • Acetaminophen is the recommended first line sales each year (Saskatchewan Health-Drug Plan agent for osteoarthritis data 1996). Despite the wide selection, NSAIDs • are more alike than different. Although they do Misoprostol is the only approved agent for differ in chemical structure, pharmacokinetics, and prophylaxis of NSAID-induced ulcers and is to some degree pharmacodynamics, they share recommended in high risk patients if NSAIDS similar mechanisms of action, efficacy, and adverse cannot be avoided. effects. week or more to become established. For this EFFICACY reason, an adequate trial of 1-2 weeks should be NSAIDs work by inhibiting cyclooxygenase (COX) allowed before increasing the dose or changing to and subsequent prostaglandin synthesis as well as another NSAID.
    [Show full text]
  • Food and Drug Administration, HHS § 201.323
    Food and Drug Administration, HHS § 201.323 liver damage or gastrointestinal bleed- calcium, choline salicylate, magnesium ing). OTC drug products containing in- salicylate, or sodium salicylate] or ternal analgesic/antipyretic active in- other pain relievers/fever reducers. [Ac- gredients may cause similar adverse ef- etaminophen and (insert one nonste- fects. FDA concludes that the labeling roidal anti-inflammatory analgesic/ of OTC drug products containing inter- antipyretic ingredient—including, but nal analgesic/antipyretic active ingre- not limited to aspirin, carbaspirin cal- dients should advise consumers with a cium, choline salicylate, magnesium history of heavy alcohol use to consult salicylate, or sodium salicylate] may a physician. Accordingly, any OTC cause liver damage and stomach bleed- drug product, labeled for adult use, ing.’’ containing any internal analgesic/anti- (b) Requirements to supplement ap- pyretic active ingredients (including, proved application. Holders of approved but not limited to, acetaminophen, as- applications for OTC drug products pirin, carbaspirin calcium, choline sa- that contain internal analgesic/anti- licylate, ibuprofen, ketoprofen, magne- pyretic active ingredients that are sub- sium salicylate, naproxen sodium, and ject to the requirements of paragraph sodium salicylate) alone or in combina- (a) of this section must submit supple- tion shall bear an alcohol warning ments under § 314.70(c) of this chapter statement in its labeling as follows: to include the required warning in the (1) Acetaminophen. ‘‘Alcohol Warn- product’s labeling. Such labeling may ing’’ [heading in boldface type]: ‘‘If you be put into use without advance ap- consume 3 or more alcoholic drinks proval of FDA provided it includes the every day, ask your doctor whether exact information included in para- you should take acetaminophen or graph (a) of this section.
    [Show full text]
  • New Zealand Data Sheet 1
    New Zealand Data Sheet 1. PRODUCT NAME NAXEN® 250 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each NAXEN 250 mg tablet contains 250 mg of Naproxen For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM NAXEN 250 mg tablets are yellow, biconvex, round tablet of 11 mm diameter with one face engraved NX250 and having a bisecting score. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications NAXEN is indicated in adults for the relief of symptoms associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendonitis and bursitis, acute gout and primary dysmenorrhoea. NAXEN is indicated in children for juvenile arthritis. 4.2. Dose and method of administration After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used (see Section 4.4). During long-term administration the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. A lower daily dose may suffice for long-term administration. In patients who tolerate lower doses well, the dose may be increased to 1000 mg per day when a higher level of anti-inflammatory/analgesic 1 | P a g e activity is required. When treating patients with naproxen 1000 mg/day, the physician should observe sufficient increased clinical benefit to offset the potential increased risk. Dose Adults For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis Initial therapy: The usual dose is 500-1000 mg per day taken in two doses at 12 hour intervals.
    [Show full text]
  • Colonoscopy Instructions
    Colonoscopy Checklist Five days before your colonoscopy: Stop any medications that thin the blood (see list below) Discuss the discontinuation of these medications with your primary care physician to ensure that it is safe to stop them Three days before your colonoscopy: Stop eating high fiber foods including nuts, corn, popcorn, raw fruits, vegetables, and bran Stop fiber supplements The day before your colonoscopy: Have a normal breakfast If your colonoscopy is scheduled before noon the following day, do not have any lunch If your colonoscopy is scheduled after noon, have a light lunch Have clear liquids for the rest of the day (see below) Start prep as instructed by your physician Do not have anything to eat or drink after midnight The day of your colonoscopy: Take your blood pressure medications with a sip of water Make sure you bring your driver’s license or photo ID and leave valuables and jewelry at home Clear Liquid Diet Water Any kind of soft drink (ginger ale, cola, tonic, etc) Gatorade Apple Juice Orange Juice without pulp Lemonade Tea/Coffee (without milk) Dietary supplements (Ensure, Boost, Enlive, etc) Clear broth (vegetable, chicken, or beef) Jell‐O (stay away from red, blue, or purple colors) Ice pops without milk or fruit bits Honey or sugar NO DAIRY PRODUCTS Medications to stop prior to colonoscopy Below is a list of many medications (but not all) that fall into these categories. It is important to remember that there are hundreds of over‐the‐counter medications that contain NSAIDs or aspirin, so it is important to carefully read the label of any medication that you are taking (prescription or over‐the‐counter).
    [Show full text]
  • Salicylate, Diflunisal and Their Metabolites Inhibit CBP/P300 and Exhibit Anticancer Activity
    RESEARCH ARTICLE Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity Kotaro Shirakawa1,2,3,4, Lan Wang5,6, Na Man5,6, Jasna Maksimoska7,8, Alexander W Sorum9, Hyung W Lim1,2, Intelly S Lee1,2, Tadahiro Shimazu1,2, John C Newman1,2, Sebastian Schro¨ der1,2, Melanie Ott1,2, Ronen Marmorstein7,8, Jordan Meier9, Stephen Nimer5,6, Eric Verdin1,2* 1Gladstone Institutes, University of California, San Francisco, United States; 2Department of Medicine, University of California, San Francisco, United States; 3Department of Hematology and Oncology, Kyoto University, Kyoto, Japan; 4Graduate School of Medicine, Kyoto University, Kyoto, Japan; 5University of Miami, Gables, United States; 6Sylvester Comprehensive Cancer Center, Miami, United States; 7Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States; 8Department of Biochemistry and Biophysics, Abramson Family Cancer Research Institute, Philadelphia, United States; 9Chemical Biology Laboratory, National Cancer Institute, Frederick, United States Abstract Salicylate and acetylsalicylic acid are potent and widely used anti-inflammatory drugs. They are thought to exert their therapeutic effects through multiple mechanisms, including the inhibition of cyclo-oxygenases, modulation of NF-kB activity, and direct activation of AMPK. However, the full spectrum of their activities is incompletely understood. Here we show that salicylate specifically inhibits CBP and p300 lysine acetyltransferase activity in vitro by direct *For correspondence: everdin@ competition with acetyl-Coenzyme A at the catalytic site. We used a chemical structure-similarity gladstone.ucsf.edu search to identify another anti-inflammatory drug, diflunisal, that inhibits p300 more potently than salicylate. At concentrations attainable in human plasma after oral administration, both salicylate Competing interests: The and diflunisal blocked the acetylation of lysine residues on histone and non-histone proteins in cells.
    [Show full text]
  • (Ketorolac Tromethamine Tablets) Rx Only WARNING TORADOL
    TORADOL ORAL (ketorolac tromethamine tablets) Rx only WARNING TORADOLORAL (ketorolac tromethamine), a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of TORADOLORAL and ketorolac tromethamine should not exceed 5 days. TORADOLORAL is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of TORADOLORAL beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK Ketorolac tromethamine, including TORADOL can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, TORADOL is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). CARDIOVASCULAR RISK NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS and CLINICAL STUDIES). TORADOL is CONTRAINDICATED for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
    [Show full text]
  • The Challenge of Drug-Induced Aseptic Meningitis Revisited
    Letters cardioverter-defibrillator generator replacements and upgrade procedures: brospinal fluid (CSF) findings and reviews added to the litera- results from the REPLACE registry. Circulation. 2010;122(16):1553-1561. ture from 1999 to date. Tables have been assembled from 6. Kramer DB, Buxton AE, Zimetbaum PJ. Time for a change: a new approach to information derived from 192 studies (these data are avail- ICD replacement. N Engl J Med. 2012;366(4):291-293. able from the authors on request). The Challenge of Drug-Induced Aseptic Results | Four groups of drugs continue to be associated Meningitis Revisited with DIAM (Table 1): nonsteroidal anti-inflammatory Cases of drug-induced aseptic meningitis (DIAM) are likely drugs (NSAIDs), antibiotics, immunosuppressive- underreported, and only a few reviews of the literature have immunomodulatory (IS-IM), and antiepileptic drugs.1 Prior been performed. We have updated (to February 2014) a pre- exposure to the associated drug was present in 26% to 35% vious review (1999)1 to identify newer agents associated with of cases (Table 1). The interval between exposure and men- DIAM, as well as distinctive new features. ingitis ranged from minutes to 5 months (Table 1). Most patients presented with headache, fever, meningismus, and Methods | Using the MEDLINE database, we searched the lit- mental status changes (Table 2). Underlying systemic disor- erature to February 2014 and included those cases with cere- ders were often present, particularly systemic lupus ery- Table 1. Drugs Involved in Drug-Induced
    [Show full text]
  • Efficacy of Ketoprofen Vs. Ibuprofen and Diclofenac: a Systematic Review of the Literature and Meta-Analysis P
    Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis P. Sarzi-Puttini1, F. Atzeni1, L. Lanata2, M. Bagnasco2 1Rheumatology Unit, L. Sacco University Hospital, Milan, Italy; 2Medical Department, Dompé SpA, Milan, Italy. Abstract Objective The aim of this systematic review of the literature and meta-analysis of randomised controlled trials (RCTs) was to compare the efficacy of orally administered ketoprofen with that of ibuprofen and/or diclofenac. Methods The literature was systematically reviewed in accordance with the Cochrane Collaboration guidelines. The search was restricted to randomised clinical trials published in the Medline and Embase databases up to June 2011, and comparing the efficacy of oral ketoprofen (50–200 mg/day) with ibuprofen (600-1800 mg/day) or diclofenac (75–150 mg/day). Results A total of 13 RCTs involving 898 patients met the inclusion criteria: eight comparing ketoprofen with ibuprofen, and five comparing ketoprofen with diclofenac. The results of the meta-analysis showed a statistically significant difference in efficacy in favour of ketoprofen. The difference between ketoprofen and the pooled ibuprofen/diclofenac data was also statistically significant (0.459, 95% CI 0.33-0.58; p=0.00) at all point-estimates of the mean weighted size effect. Ketoprofen was significantly superior to both diclofenac (mean = 0.422; 95% CI 0.19-0.65; p=0.0007) and ibuprofen (mean = 0.475; 95% CI 0.32-0.62; p=0.0000) at all point-estimates. Heterogeneity for the analysed efficacy outcome was not statisically significant in any of the meta-analyses. Conclusion The efficacy of orally administered ketoprofen in relieving moderate-severe pain and improving functional status and general condition was significantly better than that of ibuprofen and/or diclofenac.
    [Show full text]